Adnexus Therapeutics

Founded in 2002, Adnexus Therapeutics is developing new class of therapeutic compounds. The company was acquired in 2007 by Bristol-Myers Squibb Company (NYSE: BMY) for $505M. The acquisition is helping to advance Bristol-Myers Squibb’s biologics strategy across therapeutic verticals, including a cancer drug, Angiocept.


Company Profile

Adnexus Therapeutics Logo
  • Founded: 2002